Ipilimumab-induced colitis: A new challenge for gastroenterologists;Colitis secundaria a ipilimumab: Un nuevo reto para el gastroenterólogo

Gastroenterologia y Hepatologia

Volumn 39, Issue 3, 2016, Pages 233-238

  Mesonero, Francisco ^a   López Sanromán, Antonio ^a   Madariaga, Ainhoa ^a   Soria, Ainara ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Adverse event; Colitis; Infliximab, Melanoma; Ipilimumab

Indexed keywords

IPILIMUMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADVERSE DRUG REACTION; COLITIS; DIFFERENTIAL DIAGNOSIS; GASTROENTEROLOGIST; HUMAN; IPILIMUMAB INDUCED COLITIS; SHORT SURVEY; SYMPTOMATOLOGY; TREATMENT INDICATION; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; GASTROENTEROLOGY;

ANTIBODIES, MONOCLONAL; COLITIS; GASTROENTEROLOGY; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84959164246     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2015.06.005     Document Type: Short Survey

References (48)

1. Marín I., Menchén L., Gomollón F. Diagnóstico diferencial de la enfermedad inflamatoria intestinal. Elsevier Doyma 2012.
2. Gaïes E., Ouanes L., Trabelsi S., Salouage I., Klouz A., Daghfous R., et al. Drug induced colitis: Review article. Therapie 2010, 65:249-253.
3. Krishnamurthy SS, Drews RE, Savarese DMF. Enterotoxicity of chemotherapeutic agents [monografía en Internet]. En: UpToDate, 2014. [consultado 15 Feb 2015]. Disponible en: http://www.uptodate.com/.
4. Davila M., Bresalier RSl Gastrointestinal complications of oncologic therapy. Nat Clin Pract Gastroenterol Hepatol 2008, 5:682-696.
5. Kaehler K.C., Piel S., Livingstone E., Schilling B., Hauschild A., Schadendorf D. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: Identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 2010, 37:485-498.
6. Hamid O., Chin K., Li J., Neyns B., Linette G., Negrier S., et al. Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase ii, randomized, dose-ranging study. J Clin Oncol. 2008, S26:9025.
7. Peggs K.S., Quezada S.A., Korman A.J., Allison J.P. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Inmunol 2006, 18:206-213.
8. Wolchok J.D., Neyns B., Linette G., Negrier S., Lutzky J., Thomas L., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010, 11:155-164.
9. O'Day S., Ibrahim R., DePril V. Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on 1 or more prior therapies. J Clin Oncol. 2008, 26(S15):9021.
10. Hodi F.S., ÓDay S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010, 363:711-723.
11. Prieto P.A., Yang J.C., Sherry R.M., Hughes M.S., Kammula U.S., White D.E., et al. Cytotoxic T lymphocyte-associated antigen 4 blockade with ipilimumab: Long-term follow-up of 179 patients with metastatic melanoma. J Clin Oncol. 2010, 28(s7):8544.
12. Merrill S.P., Reynolds P., Kalra A., Biehl J., Vandivier R.W., Mueller S.W., et al. Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient. Ann Pharmacother 2014, 48:806.
13. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., Sharpe A.H., et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3:541-547.
14. Jeffreys W., Kähler K.C., Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncology 2012, 30:2691-2697.
15. Lebbe C, O'Day SJ, Chiarion-Sileni V. Analysis of the onset and resolution of immune-related adverse events during treatment with ipilimumab in patients with metastatic melanoma. Perspectives in Melanoma XII; October 2-4, 2008; Scheveningen/The Hague, Netherlands. Oral Abstract O-015.
16. Burdine L., Lai K., Laryea J.A. Ipilimumab-induced colonic perforation. Journal of Surgical Case Reports 2014.
17. Hinds A.M., Ahmad D.S., Muenster J.E., Berg Z.M., López K.T., Holly J.S.L. Ipilimumab-induced colitis: A rare but serious side effect. Endoscopy 2014, 46:E308-E309.
18. Berman D., Parker S.M., Siegel J., Chasalow S.D., Weber J., Galbraith S., et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advance melanoma. Cancer Inmunity 2010, 10:11.
19. Freeman H.J. Colitis associated with biological agents. World J Gastroenterol. 2012, 18:1871-1874.
20. El Fassi D., Nielsen C.H., Kjeldsen J., Clemmensen O., Hegedüs L. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut 2008, 57:714-715.
21. Goetz M., Atreya R., Ghalibafian M., Galle P.R., Neurath M.F. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis 2007, 13:1365-1368.
22. Yazisiz V., Avci A.B., Erbasan F., Yildirim B., Terzioğlu E. Developmentof Crohn's disease following anti-tumour necrosis factor therapy (etanercept). Colorectal Dis 2008, 10:953-954.
23. Song I.H., Appel H., Haibel H., Loddenkemper C., Braun J., Sieper J., et al. New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept. J Rheumatol 2008, 35:532-536.
24. Haraoui B., Krelenbaum M. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: Possible mechanisms of action. Semin Arthritis Rheum 2009, 39:176-181.
25. Quinton J.F., Sendid B., Reumaux D., Duthilleul P., Cortot A., Grandbastien B., et al. AntiSaccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: Prevalence and diagnostic role. Gut 1998, 42:788-791.
26. Landers C.J., Cohavy O., Misra R., Yang H., Lin Y., Braun J., et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto-and microbial antigens. Gastroenterology 2002, 123:689-699.
27. Repnik K., Potocnik U. CTLA4 CT60 single-nucleotide polymorphism is associated with Slovenian inflammatory bowel disease patients and regulates expression of CTLA4 isoforms. DNA Cell Biol 2010, 29:603-610.
28. Hradsky O., Dusatkova P., Lenicek M., Bronsky J., Nevoral J., Vitek L., et al. The CTLA4 variants may interact with theIL23R -and NOD2 -conferred risk in development of Crohn's disease. BMC Medical Genetics 2010, 11:91.
29. Nacional Cancer Institute: Common terminology criteria for adverse events. Department of health and human services. National Institutes of health, 2010.
30. Andreyev J., Ross P., Donnellan C., Lennan E., Leonard P., Waters C., et al. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol 2014, 15:447-460.
31. Minor D.R., Chin K., Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm 2009, 24:321-325.
32. Johnston R.L., Lutzky J., Chodhry A., Barkin J.S. Cytotoxic T lymphocyte -associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 2009, 54:2538-2540.
33. Pagés C., Gornet J.M., Monsel G., Allez M., Bertheau P., Bagot M., et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res 2013, 23:227-230.
34. Ledingham J., Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005, 44:157-163. British Society for Rheumatology Standards, Guidelines and Audit Working Group.
35. Dignass A., Van Assche G., Lindsay J.O., Lémann M., Söderholm J., Colombel J.F., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010, 4:28-62.
36. Bernheim O., Colombel J.F., Ullman T.A., Laharie D., Beaugerie L., Itzkowitz S. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut 2013, 62:1523-1528.
37. Nardone B., Hammel J.A., Raisch D.W., Weaver L.L., Scheider D., West D.P. Melanoma associated with tumor necrosis factor alpha-inhibitors: A research of adverse drugs events and reports (RADAR) project. Br J Dermatol 2014, 170:1170-1172.
38. Attia P., Phan G.Q., Maker A.V., Robinson M.R., Quezado M.M., Yang J.C., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005, 23:6043-6053.
39. Downey S.G., Klapper J.A., Smith F.O., Yang J.C., Sherry R.M., Royal R.E., et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007, 13:6681-6688.
40. Lutzky J., Wolchok J., Hamid O., Lebbe C., Pehamberger H., Linette G., et al. Association between immune-related adverse events (irAEs) and disease control or overall survival in patients with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol 2009, 27(S15):9034.
41. Ribas A., Hodi F.S., Kefford R., Hamid O., Daud A., Wolchok J.D., et al. Efficacy and safety of the anti PD-1 monoclonal antibody in 411 patients with melanoma. J Clin Oncol 2014, 32(S5):9000.
42. Hamid O., Robert C., Daud A.F., Hodi F.S., Wen-Jen H., Kefford R., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Eng J Med 2013, 369:134.
43. Robert C., Long G.V., Brady B., Dutriaux C., Maio M., Mortier L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015, 372:320-330.
44. Gielisse EAR, de Boer NKH. Ipilimumab in a patient with known Crohn's disease: To give or not to give? Journal Crohns Colitis 2014;12:1742.
45. Lynch T.J., Bondarenko I., Luft A., Serwatowski P., Barlesi F., Chacko R., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage iiiB/iv non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase ii study. J Clin Oncol. 2012, 30:2046-2054.
46. Slovin S.F., Higano C.S., Hamid O., Tejmani S., Harzstark A., Alumkel J.J., et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013, 24:1813-1821.
47. Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid O., Kefford R., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014, 384:1109-1117.
48. Ansell S.M., Lesokhin A.M., Borrello I., Halwani A., Scott E.C., Gutierrez M., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015, 372:311-319.